Biography

About Kevin

Medical affairs has shaped my ability to connect science, strategy, and stakeholders to drive meaningful outcomes for patients and healthcare communities.

Kevin leads our Medical Practice at Acumetis.  He is a skilled strategist, facilitator and trainer on a broad range of topics bringing a wealth of experience and knowledge from his time working in Medical Affairs to the Acumetis team.

He has extensive experience helping teams develop medical strategies that drive impact within cross-functional environments.

Kevin has worked in healthcare since 1994, starting work in his local pharmacy before studying Pharmacy at the University of Bath and beginning his professional career in the NHS, specializing in HIV medicine.

In 2005 he joined Roche, working as a sales representative, before starting a 15-year journey in Medical Affairs at Roche and then Allergan, where he led country medical teams Ex-US and led global medical strategies.

In 2021, Kevin expanded his experience taking on commercial roles at Mundipharma, including an assignment as General Manager for Italy. He began freelancing in 2024 and joined Acumetis in 2025.

Back to leadership team

Professional skills
and industry expertise

Leadership

  • Medical affairs practice lead
  • Previous experience as VP Medical Affairs in Global Pharma companies

Specialty

  • Medical Strategy
  • Advisory boards and insights
  • Tactical planning

Key Projects

  • Strategic plan development for a global medical device organization 
  • Patient Group Advisory Boards for US/Europe
  • Organizational implementation of Joint Clinical Assessment (JCA)

Therapeutic Areas

  • Ophthalmology
  • Infectious Diseases
  • Cardiovascular/Renal
  • Rare Disease
Authored Posts

Published works and authored insights

Three business people sitting at table collaborating
May 22, 2026
Strategic launch in a rare hematologic disease
Explore how Acumetis supported launch readiness for a novel rare hematologic disease therapy through scientific positioning, stakeholder engagement, KOL insights, and cross-functional Medical Affairs strategy.
Top down view of a river next to a shore
May 8, 2026
Optimizing Clinical Endpoints for Phase III Design
A Medical Affairs case study demonstrating how evidence review and stakeholder insight were used to refine clinically meaningful endpoints and support Phase III trial design and regulatory dialogue.
Abstract image of different shaped holes in building
May 8, 2026
Generative AI in publications development: Innovation with oversight
Explore how generative AI can enhance medical publication development with the oversight, rigor, and scientific integrity required by Medical Affairs teams.
Top down view of a river tributaries on sand
April 6, 2026
Communication strategy for novel MOA in neurological disorder
To support a novel mechanism of action in a complex neurological indication, Acumetis delivered a focused life sciences commercialization consulting strategy that aligned science, stakeholders, and evidence generation. By integrating...